Key facts
- This page summarizes Christopher Simon's Form 4 filing for HAEMONETICS CORP (HAE).
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 20 May 2021, 17:55.
Christopher Simon - 18 May 2021 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
- Issuer symbol
- HAE
- Transactions as of
- 18 May 2021
- Net transaction value
- -$56,515
- Form type
- 4
- Filing time
- 20 May 2021, 17:55:36 UTC
- Previous filing
- 18 May 2021
- Next filing
- 09 Jun 2021
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Christopher Simon filed Form 4 for HAEMONETICS CORP (HAE) on 20 May 2021.
Change
- Previous filing in this sequence was filed on 18 May 2021.
- Current net transaction value: -$56,515.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported transactions
HAE
transaction
Common Stock
Award
- Transaction value
- Shares
- +26,515
- Change %
- +16%
- Price
- Shares after
- 196,745
- Date
- 18 May 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
HAE
transaction
Common Stock
Sale
- Transaction value
- $56,515
- Shares
- -1,024
- Change %
- -0.52%
- Price
- $55.19
- Shares after
- 195,721
- Date
- 19 May 2021
- Ownership
- Direct
- Footnotes
- F3, F4
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
HAE
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +71,733
- Change %
- Price
- $0.000000
- Shares after
- 71,733
- Date
- 18 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 71,733
- Exercise price
- $56.57
- Footnotes
- F5
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. |
| F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| F3 | This number includes unvested RSUs previously reported. |
| F4 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| F5 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |